Compare ING Groep NV (ING) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs State Street SPDR S&P Biotech ETF — how do they compare? ING Groep NV trades at $33.37 (market cap $93.76B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: ING Groep NV is far larger — about 9.3× State Street SPDR S&P Biotech ETF's market cap, and ING Groep NV pays a 3.95% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ING | XBI | |
|---|---|---|
Market Cap | $93.76B | $10.11B |
Volume | 4,620,220 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $37.27 | $169.55 |
52-Week Low | $23.66 | $104.99 |
Typical Hold Time | 94 Days | 38 Days |
Enterprise Value | $236.48B | — |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.43, down 1.44% with a bearish technical outlook. The company shows strong fundamentals with consistent earnings beats, a 28.34% net margin, and positive analyst sentiment (64.71% buy ratings). Recent news highlights management's raised ROE target to 16% for 2027 and upgraded revenue guidance, though cash flow trends remain negative.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include persistent negative cash flows and regulatory scrutiny in Australia. The stock presents value with a reasonable P/E of 12.86, supported by dividend payments and institutional confidence.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
